Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Ray-Coquard, Isabelle, Braicu, Ioana, Berger, Regina, Mahner, Sven, Sehouli, Jalid, Pujade-Lauraine, Eric, Cassier, Philippe Alexandre, Moll, Ute Martha, Ulmer, Hanno, Leunen, Karin, Zeimet, Alain Gustave, Marth, Christian, Vergote, Ignace, Concin, Nicole
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746955/
https://ncbi.nlm.nih.gov/pubmed/31552170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00832
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados